Actively Recruiting
Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder
Led by Hospital de Clinicas de Porto Alegre · Updated on 2016-11-01
600
Participants Needed
1
Research Sites
1608 weeks
Total Duration
On this page
Sponsors
H
Hospital de Clinicas de Porto Alegre
Lead Sponsor
F
Federal University of Rio Grande do Sul
Collaborating Sponsor
AI-Summary
What this Trial Is About
Methylphenidate (MPH) is the first-line pharmacological treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Nevertheless, there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.
CONDITIONS
Official Title
Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder
Who Can Participate
Eligibility Criteria
You may qualify if you...
- White Brazilian of European descent
- Diagnosis of ADHD according to DSM-IV criteria
- Eligible for immediate-release methylphenidate (IR-MPH) treatment
- Age 18 years or older
You will not qualify if you...
- Contraindication to immediate-release methylphenidate use
- Current use of stimulant treatment
- Clinically significant neurological disease affecting cognition (e.g., delirium, dementia, epilepsy, head trauma, multiple sclerosis)
- Current or past history of psychosis
- Estimated intelligence quotient score below 70
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Program on Attention-Deficit/Hyperactivity Disorder (PRODAH); Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil, 90035-903
Actively Recruiting
Research Team
E
Eugênio H Grevet, MD, PhD
CONTACT
C
Claiton HD Bau, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here